VM26 therapy in children with drug-refractory lymphocytic leukemia

Gaston Rivera; Gary V. Dahl; Sharon B. Murphy; W. P. Bowman; R. J. Aur; Thomas; L. Avery; J. V. Simone

doi:10.1007/BF00254541

VM26 therapy in children with drug-refractory lymphocytic leukemia

Gaston Rivera, Gary V. Dahl, Sharon B. Murphy, W. P. Bowman, R. J. Aur, Thomas, L. Avery, J. V. Simone

Research output: Contribution to journal › Article › peer-review

Abstract

The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.

Original language	English
Pages (from-to)	169-172
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	7
Issue number	2-3
DOIs	https://doi.org/10.1007/BF00254541
State	Published - Apr 1982

Access to Document

10.1007/BF00254541

Cite this

@article{0318d189d27a41989d1d12a4a0cc32a4,

title = "VM26 therapy in children with drug-refractory lymphocytic leukemia",

abstract = "The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.",

author = "Gaston Rivera and Dahl, {Gary V.} and Murphy, {Sharon B.} and Bowman, {W. P.} and Aur, {R. J.} and Thomas and L. Avery and Simone, {J. V.}",

year = "1982",

month = apr,

doi = "10.1007/BF00254541",

language = "English",

volume = "7",

pages = "169--172",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2-3",

}

TY - JOUR

T1 - VM26 therapy in children with drug-refractory lymphocytic leukemia

AU - Rivera, Gaston

AU - Dahl, Gary V.

AU - Murphy, Sharon B.

AU - Bowman, W. P.

AU - Aur, R. J.

AU - Thomas,

AU - Avery, L.

AU - Simone, J. V.

PY - 1982/4

Y1 - 1982/4

N2 - The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.

AB - The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.

UR - http://www.scopus.com/inward/record.url?scp=0020040617&partnerID=8YFLogxK

U2 - 10.1007/BF00254541

DO - 10.1007/BF00254541

M3 - Article

C2 - 7083458

AN - SCOPUS:0020040617

SN - 0344-5704

VL - 7

SP - 169

EP - 172

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2-3

ER -

VM26 therapy in children with drug-refractory lymphocytic leukemia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this